{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T01:12:34Z","timestamp":1759799554018,"version":"build-2065373602"},"reference-count":43,"publisher":"Georg Thieme Verlag KG","issue":"08","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Res (Stuttg)"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fructosamine-3-kinase (FN3K), a deglycating enzyme originally studied in the\n                    context of diabetes, has recently emerged as a pivotal modulator of redox\n                    homeostasis and therapeutic resistance in cancer. FN3K catalyzes the removal of\n                    early glycation adducts, thereby stabilizing redox-sensitive proteins such as\n                    Nuclear factor erythroid 2\u2013related factor 2 (Nrf2), a key transcriptional\n                    regulator of antioxidant defense. This review explores the evolving role of FN3K\n                    in tumor metabolism, highlighting its expression patterns across cancer types,\n                    structural features amenable to therapeutic targeting, and mechanistic interplay\n                    with the Nrf2 pathway. Emphasis is placed on FDA-approved drugs with\n                    FN3K-modulatory potential, evaluated through computational modeling, docking\n                    simulations, and structure \u2013 activity insights. The analysis reveals a dual\n                    opportunity: to repurpose redox-active agents as FN3K inhibitors and to exploit\n                    FN3K as a biomarker for redox stratification in precision oncology. Despite\n                    promising in silico data and preclinical correlations, challenges remain \u2013\n                    particularly in achieving target selectivity, overcoming structural limitations,\n                    and validating pharmacodynamic markers. Addressing these barriers through\n                    integrated translational strategies could unlock FN3K as a tractable node in\n                    redox-driven cancer therapy.<\/jats:p>","DOI":"10.1055\/a-2677-4956","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T22:47:00Z","timestamp":1757371620000},"page":"295-307","source":"Crossref","is-referenced-by-count":0,"title":["Repurposing FDA-Approved Drugs as Fructosamine-3-Kinase Inhibitors: A\n                    Mechanistic and Translational Approach to Redox-Driven Cancer\n                    Therapy"],"prefix":"10.1055","volume":"75","author":[{"given":"Erica","family":"Alves","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS\n                    Academy of Higher Education & Research, Mysore, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gurupadayya","family":"Bannimath","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS\n                    Academy of Higher Education & Research, Mysore, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabitha","family":"Prabhakaran","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS\n                    Academy of Higher Education & Research, Mysore, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12943-024-02165-x","article-title":"Metabolic reprogramming and therapeutic resistance in primary and metastatic\n                    breast cancer","volume":"23","author":"S Liu","year":"2024","journal-title":"Mol Cancer"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.3390\/cells10051056","article-title":"Mechanisms of metabolic reprogramming in cancer cells supporting enhanced growth\n                    and proliferation","volume":"10","author":"C Schiliro","year":"2021","journal-title":"Cells"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12943-024-02119-3","article-title":"Altered metabolism in cancer: insights into energy pathways and therapeutic\n                    targets","volume":"23","author":"M Tufail","year":"2024","journal-title":"Mol Cancer"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.3390\/cancers16203513","article-title":"Insights into metabolic reprogramming in tumor evolution and therapy","volume":"16","author":"C F Chiu","year":"2024","journal-title":"Cancers (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/imm.13871","article-title":"Metabolic reprogramming in cancer: implications for immunosuppressive\n                    microenvironment","volume":"174","author":"D Aden","year":"2025","journal-title":"Immunology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","article-title":"The hallmarks of cancer metabolism: still emerging","volume":"34","author":"N N Pavlova","year":"2022","journal-title":"Cell Metab"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.3390\/biomedicines9121942","article-title":"Targeting the interplay between cancer metabolic reprogramming and cell death\n                    pathways as a viable therapeutic path","volume":"9","author":"E Iessi","year":"2021","journal-title":"Biomedicines"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1172\/JCI72391","article-title":"Exploiting tumor metabolism: challenges for clinical translation","volume":"123","author":"M G Vander Heiden","year":"2013","journal-title":"J Clin Invest"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"104438","DOI":"10.1016\/j.critrevonc.2024.104438","article-title":"Metabolic vulnerabilities in cancer: a new therapeutic strategy","volume":"201","author":"M El-Tanani","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/embor.2012.176","article-title":"Challenges in targeting cancer metabolism for cancer therapy","volume":"13","author":"R Yamaguchi","year":"2012","journal-title":"EMBO Rep"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1111\/cas.15279","article-title":"Cancer metabolism challenges genomic instability and clonal evolution as\n                    therapeutic targets","volume":"113","author":"Y Takeda","year":"2022","journal-title":"Cancer Sci"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40164-024-00482-x","article-title":"Cancer metabolism and carcinogenesis","volume":"13","author":"J Yang","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s43556-020-00012-1","article-title":"Cancer metabolism and intervention therapy","volume":"2","author":"H Zhao","year":"2021","journal-title":"Mol Biomed"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"104037","DOI":"10.1016\/j.critrevonc.2023.104037","article-title":"Therapeutic strategies targeting metabolic characteristics of cancer cells","volume":"187","author":"R Bai","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.3390\/ijms23084280","article-title":"Drug repurposing in cancer therapy: influence of patient's genetic\n                    background in breast cancer treatment","volume":"23","author":"R Rodrigues","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nrclinonc.2015.169","article-title":"Drug repurposing in oncology \u2013 patient and health systems opportunities","volume":"12","author":"F Bertolini","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3332\/ecancer.2014.442","article-title":"The Repurposing Drugs in Oncology (ReDO) Project","volume":"8","author":"P Pantziarka","year":"2014","journal-title":"Ecancermedicalscience"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.3390\/cancers15112972","article-title":"Drug repurposing in oncology: a systematic review of randomized controlled\n                    clinical trials","volume":"15","author":"I Ioakeim-Skoufa","year":"2023","journal-title":"Cancers (Basel)"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.2174\/0929867327999200820124111","article-title":"Drug repurposing in oncology: current evidence and future direction","volume":"28","author":"Z Zhang","year":"2021","journal-title":"Curr Med Chem"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"12441","DOI":"10.3390\/ijms252212441","article-title":"Drug repurposing for cancer treatment: a comprehensive review","volume":"25","author":"A H Al Khzem","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.bbcan.2019.04.005","article-title":"Drug repurposing in oncology: compounds, pathways, phenotypes and computational\n                    approaches for colorectal cancer","volume":"1871","author":"P Nowak-Sliwinska","year":"2019","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41416-023-02502-9","article-title":"Unlocking hidden potential: advancements, approaches, and obstacles in\n                    repurposing drugs for cancer therapy","volume":"130","author":"F R Weth","year":"2024","journal-title":"Br J Cancer"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.1008768","article-title":"Advantages, challenges, and impact of drug repurposing for cancer treatment","author":"R Zafar","year":"2025","journal-title":"IntechOpen"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1136\/ijgc-2022-003585","article-title":"Drug repurposing as a potential source of innovative therapies in cervical\n                    cancer","volume":"32","author":"R I Capistrano","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.2337\/diabetes.52.12.2888","article-title":"A mammalian protein homologous to fructosamine-3-kinase is a ketosamine-3-kinase\n                    acting on psicosamines and ribulosamines but not on fructosamines","volume":"52","author":"F Collard","year":"2003","journal-title":"Diabetes"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41540-024-00390-0","article-title":"Illuminating the functions of the understudied Fructosamine-3-kinase (FN3K)\n                    using a multi-omics approach reveals new links to lipid, carbon, and co-factor\n                    metabolic pathways","volume":"10","author":"S Shrestha","year":"2024","journal-title":"NPJ Syst Biol Appl"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1042\/BJ20040307","article-title":"Fructosamine 3-kinase-related protein and deglycation in human erythrocytes","volume":"382","author":"F Collard","year":"2004","journal-title":"Biochem J"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3390\/cancers13020281","article-title":"The taming of nuclear factor erythroid-2-related factor-2 (Nrf2) deglycation by\n                    fructosamine-3-kinase (FN3K)-inhibitors \u2013 a novel strategy to combat\n                    cancers","volume":"13","author":"N M Beeraka","year":"2021","journal-title":"Cancers (Basel)"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1042\/BJ20060684","article-title":"Increased protein glycation in fructosamine 3-kinase-deficient mice","volume":"399","author":"M Veiga da-Cunha","year":"2006","journal-title":"Biochem J"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"46606","DOI":"10.1074\/jbc.M407678200","article-title":"Tissue distribution and evolution of fructosamine 3-kinase and fructosamine\n                    3-kinase-related protein","volume":"279","author":"J Delplanque","year":"2004","journal-title":"J Biol Chem"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"88","DOI":"10.14744\/ejmo.2024.61033","article-title":"Expression patterns and relevance of FN3K, Nrf2, and NQO1 in breast cancers","volume":"8","author":"N M Beeraka","year":"2024","journal-title":"Eurasian J Med Oncol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.37796\/2211-8039.1130","article-title":"Evaluation of Fructosamine 3-kinase and Glyoxalase 1 activity in normal and\n                    breast cancer tissues","volume":"11","author":"T Yousefi","year":"2021","journal-title":"BioMedicine"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41467-025-56207-z","article-title":"The molecular basis of human FN3K mediated phosphorylation of glycated\n                    substrates","volume":"16","author":"A Garg","year":"2025","journal-title":"Nat Commun"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0283705","article-title":"Screening fructosamine-3-kinase (FN3K) inhibitors, a deglycating enzyme of\n                    oncogenic Nrf2: human FN3K homology modelling, docking and molecular dynamics\n                    simulations","volume":"18","author":"N M Beeraka","year":"2023","journal-title":"PLOS ONE"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.cell.2019.07.031","article-title":"The oncogenic action of NRF2 depends on de-glycation by\n                    fructosamine-3-kinase","volume":"178","author":"V R Sanghvi","year":"2019","journal-title":"Cell"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000120631","article-title":"Gene expression of fructosamine 3 kinase in patients with colorectal cancer","volume":"73","author":"M G Caruso","year":"2007","journal-title":"Oncology"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"E586","DOI":"10.1152\/ajpendo.00503.2009","article-title":"Effects of fructosamine-3-kinase deficiency on function and survival of mouse\n                    pancreatic islets after prolonged culture in high glucose or ribose\n                    concentrations","volume":"298","author":"S M Pascal","year":"2010","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref39","first-page":"c356","article-title":"Targeting breast cancer: Unveiling FN3K enzyme inhibitors via structure-based\n                    virtual screening and molecular dynamic simulation","volume":"9","author":"E Alves","year":"2024","journal-title":"Int J Novel Res Dev"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"338","DOI":"10.14744\/ejmo.2024.20665","article-title":"The FN3K\u2013Nrf2 axis: A novel therapeutic target in cancer metabolism","volume":"8","author":"E Alves","year":"2024","journal-title":"Eurasian J Med Oncol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1515\/CCLM.2011.133","article-title":"Genetic variability of the fructosamine 3-kinase gene in diabetic patients","volume":"49","author":"L Mosca","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"4360","DOI":"10.1111\/j.1742-4658.2007.05948.x","article-title":"Many fructosamine 3-kinase homologues in bacteria are\n                    ribulosamine\/erythrulosamine 3-kinases potentially involved in protein\n                    deglycation","volume":"274","author":"R Gemayel","year":"2007","journal-title":"FEBS J"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.2174\/0113816128261466231011114600","article-title":"Combinatorial Implications of Nrf2 Inhibitors with FN3K Inhibitor: In vitro\n                    Breast Cancer Study","volume":"29","author":"N M Beeraka","year":"2023","journal-title":"Curr Pharm Des"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.3390\/biomedicines9091119","article-title":"Targeted inhibition of anti-inflammatory regulator Nrf2 results in breast cancer\n                    retardation in vitro and in vivo","volume":"9","author":"V R Bovilla","year":"2021","journal-title":"Biomedicines"}],"container-title":["Drug Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2677-4956.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T22:40:23Z","timestamp":1759790423000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2677-4956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":43,"journal-issue":{"issue":"08","published-online":{"date-parts":[[2025,10,6]]},"published-print":{"date-parts":[[2025,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2677-4956","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2194-9379","2194-9387"],"issn-type":[{"type":"print","value":"2194-9379"},{"type":"electronic","value":"2194-9387"}],"subject":[],"published":{"date-parts":[[2025,9,8]]}}}